bluetongu
viru
btv
member
famili
reovirida
reemerg
anim
diseas
infect
cattl
sheep
recent
outbreak
europ
press
need
efficaci
antivir
present
identif
character
novel
virostat
molecul
btv
aminothiophenecarboxyl
acid
deriv
name
compound
virostat
efficaci
could
improv
via
chemic
modif
lead
de
novo
synthes
compound
effect
concentr
ec
determin
mm
mm
respect
cytotox
concentr
cc
mm
cc
mm
accordingli
select
index
si
btv
respect
inhibitori
effect
btvinduc
apoptosi
also
confirm
via
inhibit
activ
post
btv
infect
could
inhibit
btv
induc
cpe
even
ad
late
hpi
indic
might
act
late
stage
viral
lifecycl
could
reduc
twolog
progeni
viru
product
number
genom
viral
rna
copi
interestingli
activ
host
autophagi
viral
protein
express
inhibit
post
btv
infect
cell
treat
suggest
might
act
virostat
agent
via
inhibit
host
autophagi
activ
although
investig
might
need
pin
exact
mechan
find
suggest
compound
might
potent
lead
compound
potenti
novel
mechan
action
btv
bluetongu
viru
btv
doublestrand
rna
dsrna
viru
prototyp
viru
genu
orbiviru
within
famili
reovirida
segment
btv
dsrna
genom
encod
ten
viral
protein
vp
includ
seven
structur
protein
three
nonstructur
ns
protein
member
arbovirus
btv
transmit
certain
speci
culicoid
bite
midg
includ
c
variipenni
c
imocola
bluetongu
diseas
noncontagi
viral
diseas
affect
domest
anim
includ
sheep
cattl
primarili
well
wild
rumin
buffalo
antelop
deer
elk
camel
btv
diseas
one
import
diseas
domest
livestock
caus
billion
per
year
loss
worldwid
sheep
diseas
acut
mortal
accordingli
high
btv
list
offic
intern
de
epizooti
oie
terrestri
anim
health
code
exot
btv
also
list
usda
high
consequ
livestock
pathogen
due
econom
signific
btv
subject
extens
molecular
virolog
structur
biolog
studi
recent
develop
btv
revers
genet
system
facilit
understand
toward
btv
viral
lifecycl
structur
function
interrelationship
among
viral
protein
henc
btv
one
wellcharacter
virus
main
prevent
control
measur
endem
area
includ
activ
surveil
program
anim
quarantin
movement
restrict
vaccin
insect
control
measur
vaccin
use
effect
practic
measur
minim
loss
relat
btv
diseas
potenti
interrupt
cycl
infect
anim
vector
howev
due
complex
viru
includ
twentyfour
differ
serotyp
abil
caus
variabl
diseas
btv
still
endem
mani
region
despit
high
vaccin
coverag
sheep
cattl
outbreak
mediterranean
basin
greatest
epizoot
diseas
record
show
btv
extend
rang
northward
area
europ
never
affect
sinc
persist
mani
locat
reach
three
northern
europ
countri
includ
netherland
belgium
germani
spread
surround
countri
reach
switzerland
end
octob
vaccin
individualsanim
outbreak
prove
effect
howev
protect
individualanim
threat
may
occur
two
week
initi
vaccin
henc
drug
offer
therapeut
treatment
individualsanim
endem
area
surprisingli
antivir
current
avail
btv
diseas
recent
antibtv
drug
discoveri
implement
potenti
antivir
lead
compound
identifi
develop
valid
cytopath
effect
cpe
base
assay
led
screen
nih
molecular
librari
small
molecul
repositori
mlsmr
small
molecul
compound
studi
use
variou
primari
secondari
confirmatori
assay
confirm
structur
group
six
analog
seri
correspond
six
scaffold
enrich
within
activ
set
compar
distribut
librari
base
result
previou
studi
select
evalu
virostat
efficaci
cluster
activ
compound
particular
aminothiophenecarboxyl
acid
deriv
furthermor
aim
understand
mechan
action
variou
studi
carri
determin
viral
life
stage
compound
act
focus
virostat
compound
protect
cell
btvinduc
apoptosi
base
previous
identifi
six
compound
cluster
select
repres
compound
cluster
assess
virostat
efficaci
btv
includ
effect
concentr
ec
effect
concentr
ec
ec
lead
compound
determin
mm
mm
respect
result
shown
interestingli
four
thiophen
deriv
compound
cluster
ie
compound
show
potent
virostat
efficaci
btv
especi
aminothiophenecarboxyl
acid
deriv
use
tenconcentr
dose
respons
assay
ec
determin
mm
mm
respect
fig
b
ec
mm
mm
respect
fig
b
result
indic
could
potenti
novel
virostat
agent
btv
addit
cytotox
concentr
cc
mm
fig
b
accordingli
select
index
si
equal
ec
cc
respect
indic
compound
highli
select
btv
consid
compound
solubl
avail
select
lead
virostat
agent
evalu
includ
structureact
relationship
sar
analysi
chemic
modif
mechan
action
studi
acryloyl
amino
acid
aminothiophenecarboxyl
acid
deriv
structur
show
figur
improv
potenti
antibtv
lead
structur
framework
divid
zone
synthet
target
goal
figur
illustr
result
variat
zone
replac
furan
thiophen
pyridin
approach
involv
converg
pathway
wherebi
gewald
reaction
employ
thiophen
unit
zone
hornerwadsworthemmon
reaction
malon
acid
follow
acid
chlorid
format
provid
mean
zone
modifi
bring
unit
togeth
produc
ic
saponif
gave
sodium
salt
upon
acidif
yield
desir
final
product
fig
potenti
prodrug
ester
also
evalu
virostat
efficaci
interestingli
analog
includ
show
improv
virostat
efficaci
de
novo
synthes
analog
show
improv
virostat
efficaci
ec
mm
ec
mm
respect
fig
similarli
show
littl
toxic
cc
mm
consequ
si
compar
ec
si
ec
time
lower
si
time
higher
indic
virostat
efficaci
could
improv
via
sar
chemic
modif
lead
potent
select
virostat
agent
btv
celltiterglo
cell
viabil
assay
determin
number
viabl
cell
cultur
base
quantit
cellular
atp
present
signal
presenc
metabol
activ
live
cell
confirm
could
prevent
btvinduc
cpe
cell
morpholog
chang
differ
hpi
examin
post
btv
infect
moi
without
treatment
cpe
observ
earli
hpi
infect
cell
hpi
major
infect
cell
dislodg
plate
indic
cpe
cell
lysi
fig
mm
mm
ad
btvinfect
cell
hpi
cpe
observ
till
hpi
sign
cell
dislodg
lysi
fig
f
similar
previou
observ
uninfect
cell
treat
mm
mm
fig
e
show
overt
toxic
regard
cell
divis
morpholog
chang
compar
cell
viabil
control
cell
fig
result
confirm
btvinduc
cpe
prevent
cell
treat
previou
studi
show
btv
infect
mammalian
cell
trigger
apoptosi
lead
cpecel
lysi
vitro
virusinduc
pathogenesi
vivo
order
confirm
andor
prevent
btvinduc
cpe
via
block
apoptosi
examin
activ
infect
cell
treat
virostat
compound
differ
hpi
result
show
btvinduc
activ
main
characterist
apoptosi
inhibit
treat
cell
btvinfect
cell
treat
fig
b
result
indic
andor
could
inhibit
btvinduc
activ
prevent
btvinduc
apoptosi
consequ
cpe
cell
lysi
understand
whether
could
disrupt
product
btv
viral
lifecycl
analyz
effect
btv
progeni
product
bsr
infect
btv
moi
cell
treat
mm
mm
respect
differ
hpi
cell
supernat
collect
btv
titer
sampl
determin
convent
plaqu
assay
hpi
one
log
differ
viru
progeni
product
cell
treat
mm
mm
respect
compar
sampl
collect
btvinfect
cell
threeor
twolog
reduct
viru
progeni
product
sampl
collect
hpi
hpi
treat
respect
fig
similarli
reduct
progeni
viru
product
also
notic
supernat
sampl
treat
threeor
twolog
reduct
viru
progeni
titer
respect
compar
sampl
collect
btvinfect
supernat
without
virostat
compound
treatment
fig
inhibit
btv
viru
progeni
product
confirm
use
plaqu
reduct
assay
differ
concentr
mix
agros
overlay
appli
btv
infect
cell
moi
directli
inhibit
btv
plaqu
format
examin
hpi
effect
btv
plaqu
reduct
dosedepend
fashion
hpi
onelog
reduct
plaqu
format
observ
mm
mm
appli
btv
infect
cell
respect
appli
higher
concentr
ie
mm
infect
cell
twolog
plaqu
reduct
observ
fig
differ
term
size
format
plaqu
result
shown
result
show
could
reduc
viral
plaqu
format
directli
sinc
show
overt
toxic
vitro
yet
prevent
btv
induc
cpeapoptosiscel
lysi
reduc
viru
progeni
product
initi
mechan
action
studi
timeofaddit
assay
determin
possibl
stage
viral
lifecycl
could
affect
order
observ
enhanc
reduct
virostat
efficaci
differ
time
addit
use
two
concentr
virostat
compound
ie
mm
mm
mm
mm
respect
first
observ
ad
virostat
compound
hour
prior
btv
infect
ie
hpi
chang
virostat
efficaci
result
indic
might
act
earli
stage
viral
lifecycl
viru
entri
fig
b
interestingli
compound
ad
btv
infect
cell
later
hpi
show
similar
protect
term
percentag
viabl
cell
ad
hpi
percentag
viabl
cell
decreas
treatment
sampl
compar
protect
initi
hpi
indic
less
protect
post
certain
stage
viral
lifecycl
ad
hpi
compound
show
protect
bsr
cell
btvinduc
cpe
fig
b
sinc
first
cycl
btv
viral
replic
usual
complet
infect
cell
within
hpi
result
suggest
might
act
earli
stage
btv
viral
lifecycl
includ
viru
entri
uncoat
rather
late
stage
btv
viral
lifecycl
viru
replic
packag
matur
egress
meanwhil
also
possibl
compound
may
act
host
cellular
machineri
involv
late
viral
lifecycl
determin
whether
act
btv
viral
lifecycl
directli
examin
effect
viral
genom
rna
replic
infect
cell
btv
viral
genom
rna
copi
determin
cell
supernat
sampl
use
real
time
qrtpcr
fig
b
correspond
viral
genom
rna
replic
viru
progeni
product
sampl
confirm
evalu
amount
infecti
viru
use
standard
plaqu
assay
fig
sampl
collect
post
btv
infect
divid
cell
supernat
portion
differ
time
initi
hpi
without
treatment
mm
mm
respect
infect
low
moi
viral
genom
rna
copi
progeni
viru
titer
obtain
cell
sampl
repres
event
occur
insid
cell
initi
virallif
cycl
includ
viru
entri
replic
matur
within
cell
viral
genom
rna
copi
viru
titer
supernat
sampl
denot
event
post
viru
lifecycl
insid
cell
initi
hpi
includ
amount
virus
exit
cell
earli
time
point
includ
hpi
differ
viral
genom
rna
copi
sampl
collect
supernat
cell
whether
treat
indic
earli
viral
life
cycl
entri
btv
cell
interf
fig
b
meanwhil
detect
progeni
viru
product
sampl
fig
hpi
pronounc
reduct
around
twolog
viru
genom
rna
copi
viru
titer
supernat
sampl
treatment
compar
supernat
sampl
without
treatment
supernat
sampl
collect
hpi
btv
infect
without
treatment
copi
btv
viral
genom
rna
copi
btv
viral
genom
rna
sampl
treat
respect
fig
result
indic
pronounc
effect
virostat
agent
late
stage
viral
lifecycl
howev
might
also
inhibit
viru
replic
directli
sinc
onelog
differ
viral
genom
rna
copi
viru
titer
compar
sampl
infect
cell
without
treatment
fig
confirm
effect
btv
viral
lifecycl
also
analyz
viral
protein
synthesi
cell
sampl
infect
moi
without
treatment
btv
possess
nucleosid
triphosphatas
rna
bind
helicas
activ
success
btv
lifecycl
integr
part
transcript
complex
essenti
primari
replic
moi
detect
hpi
sampl
detect
hpi
btvinfect
cell
without
treatment
fig
btvinfect
cell
treat
mm
mm
respect
either
low
detect
express
cell
hpi
fig
result
support
previou
observ
reduc
viral
protein
express
infect
low
moi
base
data
present
hypothes
might
act
host
machineriespathway
involv
viral
lifecycl
includ
autophag
pathway
autophagi
one
major
pathway
degrad
turnov
longliv
protein
organel
cell
cell
starvat
upon
variou
stimuli
viru
infect
grow
evid
suggest
autophagi
activ
particip
variou
pathogen
infect
includ
format
autophagosom
replic
influenza
viru
hepat
c
viru
dengu
viru
turnov
microtubuleassoci
protein
light
chain
ratio
biomark
reliabl
associ
format
autophagosom
also
relat
viru
replic
lead
indic
virusinduc
apoptosi
sinc
prevent
btvinduc
apoptosi
examin
activ
format
autophagi
btvinfect
cell
without
virostat
compound
treatment
infect
moi
autophagi
activ
h
post
btv
infect
level
show
differ
sampl
without
treatment
howev
hpi
turnov
btv
infect
cell
without
treatment
ratio
indic
cleav
fig
turnov
much
lower
level
mm
ad
btvinfect
cell
ratio
respect
fig
result
suggest
might
act
interf
btv
induc
autophagi
consequ
inhibit
btvinduc
cpe
result
econom
signific
model
system
btv
subject
extens
molecular
genet
structur
studi
repres
one
well
character
virus
much
effort
focus
develop
vaccin
btv
includ
attenu
btv
vlp
contrast
remain
underinvestig
util
knowledg
molecular
virolog
studi
antivir
drug
discoveri
report
character
novel
class
compound
virostat
agent
btv
compound
ie
thiophen
deriv
identifi
activ
compound
variou
assay
includ
enhanc
surviv
motor
neuron
protein
splice
variant
express
activ
alphasynuclein
bind
activ
plausibl
aminothiophenecarboxyl
acid
identifi
novel
compound
btv
potent
virostat
efficaci
low
cytotox
high
si
interestingli
preliminari
sar
analysi
lead
improv
virostat
via
de
novo
synthesi
studi
suggest
use
lead
compound
possibl
develop
novel
potent
antivir
btv
via
chemic
modif
maintain
low
toxic
high
select
major
rna
virus
induct
apoptosi
facilit
viru
dissemin
essenti
step
late
stage
viral
lifecycl
interf
host
apoptot
machineri
especi
inhibit
viru
induc
apoptosi
disrupt
success
viral
lifecycl
via
block
viru
releas
thu
host
apoptot
respons
post
viru
infect
attract
target
antivir
drug
develop
common
indispens
late
step
product
viral
lifecycl
mani
virus
previou
studi
shown
btv
infect
trigger
apoptosi
via
intrins
extrins
pathway
induct
apoptosi
involv
btvinduc
pathogenesi
vivo
mechan
action
studi
indic
activ
protect
cell
btvinduc
apoptosi
inhibit
activ
indic
target
upstream
cascad
caspas
activ
howev
bsr
cell
treat
pancaspas
inhibitor
includ
zvadfmk
cell
protect
btvinduc
apoptosi
btvinduc
cpe
observ
btv
replic
interrupt
result
shown
suggest
apoptosiscp
inhibit
mechan
action
virostat
compound
might
directli
relat
btvinduc
apoptot
pathway
rather
result
inhibit
late
step
viral
lifecycl
host
machineri
induc
upstream
apoptot
signal
interestingli
result
show
host
autophagi
machinerypathway
inhibit
andor
reliabl
autophagi
marker
downregul
btvinfect
cell
treat
compound
fig
autophagi
highli
conserv
process
eukaryot
cytoplasm
includ
excess
aberr
organel
sequest
doublemembran
vesicl
deliv
degrad
organel
lysosomevacuol
breakdown
eventu
recycl
result
macromolecul
autophagi
activ
adapt
respons
varieti
extracellular
intracellular
stimuli
includ
nutrient
depriv
hormon
therapeut
treatment
aggreg
misfold
protein
damag
organel
microbi
infect
although
autophagi
pathway
might
host
defens
mechan
differ
virus
develop
variou
strategi
counteract
antivir
mechan
andor
util
autophagi
machineri
provir
host
factor
favor
viral
replic
recent
grow
list
virus
shown
target
autophag
degrad
instanc
autophagi
activ
involv
influenza
viru
replic
trigger
autophagosom
format
increas
level
enhanc
autophag
flux
dengu
viru
also
activ
autophag
machineri
favor
viral
replic
autophagosom
act
site
translat
replic
dengu
entri
replic
link
ongo
associ
membran
endosomalautophagosom
lineag
similarli
induct
autophagi
pathway
enhanc
replic
polioviru
coronaviru
infect
dsrna
viru
rotaviru
nonstructur
protein
coloc
caplik
structur
associ
viroplasm
site
nascent
viral
rna
replic
suggest
possibl
new
mechan
involv
viru
replic
find
show
interact
autophagi
machineri
may
lead
new
research
avenu
develop
novel
antivir
interven
virusautophagi
interact
viru
entri
viru
replic
target
extens
antivir
drug
discoveri
develop
egress
dissemin
newli
synthes
progeni
viru
equal
import
relat
success
viral
infect
receiv
much
less
attent
mainli
due
lack
inform
mechan
egressdissemin
interestingli
studi
show
autophagi
may
assist
polioviru
egress
polioviru
coxsackieviru
infect
coloc
nonstructur
protein
autophagi
marker
togeth
gene
silenc
pharmacolog
experi
indic
autophagi
protein
enhanc
viral
replic
progeni
viru
yield
btv
viral
may
act
like
membran
protein
envelop
virus
respons
intracellular
traffick
bud
viru
particl
virostat
target
viru
egress
would
predict
prevent
slow
viru
releas
spread
infect
host
thu
allow
time
individu
immun
system
respond
control
infect
studi
role
autophagi
btv
progeni
viru
egressdissemin
may
help
understand
exact
mechan
action
result
extend
previou
find
show
cluster
lead
compound
prevent
btv
induc
cpe
studi
might
need
defin
exact
mechan
action
virostat
agent
studi
show
compound
may
interact
host
apoptot
machineri
rather
poss
virostat
activ
block
variou
signal
induc
host
apoptosi
find
host
autophagi
involv
btv
lifecycl
might
act
host
autophag
machineri
may
open
new
avenu
identifi
develop
novel
small
molecul
antivir
specif
interact
host
autophagi
machineri
bsr
cell
clone
deriv
babi
hamster
kidney
bhk
cell
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
carlsbad
ca
usa
supplement
fetal
calf
serum
fc
uml
penicillin
mgml
streptomycin
invitrogen
assay
unless
otherwis
note
cell
plate
dmem
optim
condit
previous
determin
includ
fc
cell
incub
grown
co
type
btv
plaqu
purifi
propag
describ
previous
titrat
standard
plaqu
assay
stock
pfuml
use
infect
indic
multipl
infect
moi
viru
replic
cell
monolay
wash
fcsfree
growth
medium
incub
virus
indic
moi
viru
adsorpt
carri
h
co
follow
incub
growth
medium
supplement
fc
variou
hour
post
infect
hpi
cell
supernat
collect
cell
sonic
cell
debri
remov
lowspe
centrifug
g
viru
titer
result
supernat
determin
bsr
cell
co
use
standard
plaqu
assay
describ
previous
cpebas
cell
viabil
assay
use
celltitergloh
luminesc
cell
viabil
kit
promega
inc
madison
wi
carri
describ
previous
cell
viabil
determin
indic
time
point
use
celltiterglo
reagent
follow
manufactur
instruct
promega
briefli
celltiterglo
buffer
lyophil
celltiterglo
substrat
promega
thaw
equilibr
room
temperatur
prior
use
homogen
celltiterglo
reagent
solut
reconstitut
mix
lyophil
enzymesubstr
buffer
reagent
accord
manufactur
instruct
meanwhil
assay
plate
also
equilibr
room
temperatur
min
equal
volum
ml
celltiterglo
reagent
ad
well
microflo
select
dispens
biotek
winooski
vt
incub
minut
room
temperatur
luminesc
signal
measur
use
synergyii
multimod
micropl
reader
biotek
integr
time
virostat
efficaci
assay
compound
carri
optim
condit
describ
previous
briefli
bsr
cell
seed
black
plate
corn
use
microflo
select
dispens
biotek
hour
incub
co
humid
ten
differ
concentr
compound
serial
dilut
ad
well
cell
infect
btv
moi
via
biotek
dispens
compound
treatment
group
btv
infect
denot
moi
includ
eight
replic
mock
infect
cell
viru
infect
control
also
includ
posit
neg
control
respect
compound
cytotox
assay
carri
fashion
except
without
btv
infect
incub
co
humid
h
cell
viabil
determin
use
celltiterglo
reagent
describ
previous
timeofaddit
assay
perform
understand
virostat
activ
previous
identifi
compound
briefli
bsr
cell
seed
incub
co
humid
cell
inocul
btv
moi
incub
optim
condit
describ
previous
select
virostat
compound
dilut
indic
concentr
ad
well
differ
time
preor
postbtv
infect
denot
hpi
indic
bsr
cell
incub
select
virostat
compound
prior
btv
infect
hpi
compound
btv
ad
cultur
simultan
treat
cell
incub
co
humid
parallel
cell
without
compound
viru
treatment
includ
mock
infect
control
cell
compound
treatment
serv
control
monitor
compound
cytotox
cell
btv
infect
without
compound
treatment
also
includ
viru
infect
control
btv
compound
treatment
group
includ
eight
replic
incub
h
cell
viabil
determin
use
celltiterglo
reagent
describ
abil
virostat
compound
inhibit
btvinduc
cpe
normal
use
control
design
assay
cell
viabil
mock
infect
cell
design
cell
viabil
btv
infect
cell
caspasegloh
apoptosi
assay
accomplish
use
caspasegloh
assay
kit
promega
follow
manufactur
instruct
cell
plate
incub
condit
well
plate
layout
similar
use
cpebas
assay
btv
infect
compound
addit
also
similar
fashion
describ
cpebas
virostat
efficaci
assay
caspasegloh
buffer
lyophil
caspasegloh
substrat
equilibr
room
temperatur
use
caspasegloh
buffer
transfer
amber
bottl
contain
caspasegloh
substrat
mix
swirl
invert
content
substrat
thoroughli
dissolv
form
caspasegloh
reagent
premix
caspaseglo
reagent
promega
ad
ratio
reagent
media
treat
cell
hpi
otherwis
note
text
minut
incub
dark
room
temperatur
luminesc
signal
read
synergyii
multimod
micropl
reader
biotek
total
rna
extract
cell
supernat
describ
trizol
ls
reagent
invitrogen
carlsbad
ca
accord
manufactur
instruct
dri
rna
pellet
resuspend
ml
depc
treatedwat
store
rtpcr
amplif
follow
manufactur
instruct
realtim
qrtpcr
carri
use
one
step
srbi
ex
taq
qrtpcr
kit
takara
japan
realtim
qrtpcr
perform
singl
tube
amplifi
product
monitor
realtim
use
fast
realtim
pcr
system
ab
appli
biosystem
two
btvspecif
primer
design
use
realtim
qrtpcr
forward
primer
revers
primer
sampl
sdspage
western
blot
analysi
prepar
boil
protein
dissoci
buffer
vv
bmercaptoethanol
wtvol
sd
vv
glycerol
mm
trishcl
ph
wtvol
bromophenol
blue
min
protein
sampl
load
sampl
buffer
electrophoresi
carri
sdspolyacrylamid
gel
protein
electroblot
immobilonp
polyvinyliden
difluorid
pvdf
membran
millipor
billerica
usa
h
use
semidri
electrotransf
apparatu
pvdf
membran
immedi
place
skim
milk
tbst
incub
overnight
step
follow
h
incub
primari
antibodi
dilut
bsa
tb
mous
monoclon
mous
monoclon
antihuman
abgent
inc
san
diego
ca
use
concentr
recommend
manufactur
blot
wash
three
time
min
tbst
incub
h
horseradish
peroxidaseconjug
secondari
antibodi
dilut
bsatbst
goat
antimous
antirabbit
secondari
antibodi
conjug
horseradish
peroxidas
bd
bioscienc
san
jose
ca
use
bound
antibodi
detect
enhanc
chemiluminesc
kit
amersham
piscataway
nj
usa
plaqu
reduct
assay
carri
plate
includ
compound
overlay
agaros
appli
directli
btv
infect
cell
cultur
describ
previous
cell
initi
inocul
btv
tenfold
seri
dilut
known
initi
btv
titer
absorb
h
co
humid
inocul
remov
wash
media
replac
agaros
mix
compound
indic
concentr
rang
mm
mm
concentr
triplic
hpi
number
plaqu
form
differ
compound
concentr
count
final
viru
titer
determin
accordingli
structur
modif
illustr
figur
prepar
intermedi
compound
follow
adapt
gewald
reaction
begin
commerci
avail
compound
achiev
modif
hornerwadsworthemmon
procedur
commerci
avail
follow
standard
acid
chlorid
format
thionyl
chlorid
combin
pursu
describ
literatur
relat
system
standard
saponif
result
produc
becam
final
product
upon
routin
acidif
fig
compound
character
high
field
nmr
bruker
high
resolut
mass
spectral
water
q
premier
api
quadrupol
tof
tandem
mass
spectromet
analys
puriti
confirm
micro
analyt
element
determin
